Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.

{"sci_version": "1.2", "schema": "https://corpus.bntrg.co.uk/sci/1.0/sci.schema.json", "id": "pmid:33983065", "kind": "science-record", "revision": 7, "content_hash": "sha256:926deeefe634120a65e9ab4654ec990a9779d37b960b9d69b0914b04399a8bce", "created_at": "2026-11-01T15:41:35Z", "updated_at": "2026-11-01T22:46:41Z", "generator": {"name": "corpus-assay-engine", "run_id": "reading-sci-2026-11-01"}, "paper": {"state": "complete", "title": "Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.", "doi": "10.1177/03000605211013550", "pmid": "33983065", "authors": ["Reaz Mahmud", "Md Mujibur Rahman", "Iftikher Alam", "Kazi Gias Uddin Ahmed", "A K M Humayon Kabir", "S K Jakaria Been Sayeed", "Mohammad Aftab Rassel", "Farhana Binte Monayem", "Md Shahidul Islam", "Mohammad Monirul Islam", "Anindita Das Barshan", "Mohammad Mahfuzul Hoque", "Md Uzzal Mallik", "Mohammad Abdullah Yusuf", "Mohammad Zaid Hossain"], "journal": "The Journal of international medical research", "year": 2021, "abstract": "OBJECTIVE: We evaluated whether ivermectin combined with doxycycline reduced the clinical recovery time in adults with COVID-19 infection.\nMETHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 symptoms randomly assigned to treatment (n = 200) and placebo (n = 200) groups. The primary outcome was duration from treatment to clinical recovery. Secondary outcomes were disease progression and persistent COVID-19 positivity by RT-PCR.\nRESULTS: Among 556 screened patients, 400 were enrolled and 363 completed follow-up. The mean patient age was 40 years, and 59% were men. The median recovery time was 7 (4-10, treatment group) and 9 (5-12, placebo group) days (hazard ratio, 0.73; 95% confidence interval, 0.60-0.90). The number of patients with a ≤7-day recovery was 61% (treatment group) and 44% (placebo groups) (hazard ratio, 0.06; 95% confidence interval, 0.04-0.09). The proportion of patients who remained RT-PCR positive on day 14 and whose disease did not progress was significantly lower in the treatment group than in the placebo group.\nCONCLUSIONS: Patients with mild-to-moderate COVID-19 infection treated with ivermectin plus doxycycline recovered earlier, were less likely to progress to more serious disease, and were more likely to be COVID-19 negative by RT-PCR on day 14.\nTRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04523831.\nDATA REPOSITORY ID: Dryad. doi:10.5061/dryad.qjq2bvqf6.", "claims": [{"id": "claim-method", "statement": "The difference in median recovery time was determined using Kaplan–Meier analysis and a log-rank test. Details of patients who were lost to follow-up, had died, or had withdrawn from the trial owing to adverse effects were censored on the final study day. Differences in the clinical improvement in the three disease categories were analyzed using logistic regression. Hazard ratios (HRs) were calculated using Cox regression analysis.", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:33983065", "locator": "sections[8] \"Statistical methods\" paragraph 3", "quote": "The difference in median recovery time was determined using Kaplan–Meier analysis and a log-rank test. Details of patients who were lost to follow-up, had died, or had withdrawn from the trial owing to adverse effects were censored on the final study day. Differences in the clinical improvement in the three disease categories were analyzed using logistic regression. Hazard ratios (HRs) were calculated using Cox regression analysis."}], "state": "complete"}, {"id": "claim-data-access", "statement": "Dryad. doi:10.5061/dryad.qjq2bvqf6", "kind": "methodological", "target": null, "evidence": [{"asset": "source:pmid:33983065", "locator": "sections[0] \"Abstract\" paragraph 6", "quote": "Dryad. doi:10.5061/dryad.qjq2bvqf6"}], "state": "complete"}], "gaps": []}, "experiment": {"state": "partial", "objective": null, "steps": [{"id": "read_published_estimate", "order": 1, "name": "Read the published estimate from the source", "kind": "other", "state": "complete", "blocked_on": null, "description": "The claim, method and evidence span published with the source article.", "duration_hours": null, "parameters": {}, "inputs": ["source:pmid:33983065"], "outputs": ["the published estimate and its evidence"], "instruments": [], "reagents": []}, {"id": "obtain_source_data", "order": 2, "name": "Obtain the source data from the named repository", "kind": "data-preparation", "state": "blocked", "blocked_on": "data:accession_absent", "description": "The GEO series accession resolves and its sample accessions are listed. This lane did not download the dataset or read its licence.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the source data with its repository provenance"], "instruments": [], "reagents": []}, {"id": "run_analysis", "order": 3, "name": "Run the published analysis", "kind": "analysis", "state": "complete", "blocked_on": null, "description": "Apply the paper's statistical method to the resolved series and compare the result with the published target.", "duration_hours": null, "parameters": {}, "inputs": [], "outputs": ["the replicated result and its comparison"], "instruments": [], "reagents": []}], "materials": [], "instruments": [], "reagents": [], "conditions": {}, "gaps": ["step:obtain_source_data blocked on data:accession_absent"]}, "data": {"state": "partial", "assets": [{"id": "source:pmid:33983065", "role": "manuscript", "format": "xml", "media_type": "application/xml", "uri": "https://doi.org/10.1177/03000605211013550", "sha256": "sha256:a20a75a4bb86b91f22c70e3e451b1f0695770c2a5b7b8001666cec411927a4b2", "bytes": 25886, "access": "open", "state": "resolved", "reader": null, "reader_status": "reader_required", "identifier": "10.1177/03000605211013550", "version": null, "note": "Full article fetched from PMC; the checksum covers the rendered section body, not the original XML bytes.", "structure": {"pmcid": "PMC8127799", "source": "europe_pmc_fulltext", "coverage": "whole_body_without_references", "text_hash_scope": "rendered_section_body"}}, {"id": "asset:table:pmid:33983065:1", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:4b06b80367d9b3c1493287fc6a2e41554dff7fb75514d9ca96d7cc87090dfad6", "bytes": 273, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[11]/table-wrap[1]#table1-03000605211013550", "version": null, "note": "Baseline characteristics of patients with COVID-19 treated with ivermectin and doxycycline or placebo.", "structure": {"pmcid": "PMC8127799", "section_index": 11, "section_title": "Patient disposition and characteristics", "row_count": 0, "column_count": 0}, "table": {"label": "Table 1.", "caption": "Baseline characteristics of patients with COVID-19 treated with ivermectin and doxycycline or placebo.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[11]/table-wrap[1]#table1-03000605211013550"}}, {"id": "asset:table:pmid:33983065:2", "role": "table", "format": "jats-table", "media_type": "application/vnd.jats.table+json", "uri": null, "sha256": "sha256:6d22d651e95318a16130aa7acf134c7f2a2690df30b3f9f53a7607097abef242", "bytes": 257, "access": "open", "state": "verified", "reader": "read_table", "reader_status": "available", "identifier": "section[11]/table-wrap[2]#table2-03000605211013550", "version": null, "note": "Outcomes of patients with COVID-19 treated with ivermectin and doxycycline or placebo.", "structure": {"pmcid": "PMC8127799", "section_index": 11, "section_title": "Patient disposition and characteristics", "row_count": 0, "column_count": 0}, "table": {"label": "Table 2.", "caption": "Outcomes of patients with COVID-19 treated with ivermectin and doxycycline or placebo.", "rows": [], "row_count": 0, "column_count": 0, "numeric_cells": 0, "header_rows": 0, "locator": "section[11]/table-wrap[2]#table2-03000605211013550"}}], "gaps": []}, "analysis": {"state": "complete", "methods": [{"id": "method-1", "family": "survival_analysis", "specific": "cox_proportional_hazards", "label": "Survival analysis", "dsl_operations": ["cox_ph"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 1.0, "band": "verbatim", "quote": "The difference in median recovery time was determined using Kaplan–Meier analysis and a log-rank test. Details of patients who were lost to follow-up, had died, or had withdrawn from the trial owing to adverse effects were censored on the final study day. Differences in the clinical improvement in the three disease categories were analyzed using logistic regression. Hazard ratios (HRs) were calculated using Cox regression analysis."}}, {"id": "method-2", "family": "survival_analysis", "specific": "log_rank_test", "label": "Survival analysis", "dsl_operations": ["logrank_test"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["time_to_event_with_censoring"], "evidence": {"score": 0.8, "band": "high", "quote": "log-rank"}}, {"id": "method-3", "family": "regression_modelling", "specific": "logistic", "label": "Regression modelling", "dsl_operations": ["glm_logit_fit"], "missing_operations": [], "expressible": true, "parameters": {}, "data_shapes": ["predictors_and_outcome"], "evidence": {"score": 0.8, "band": "high", "quote": "logistic regression"}}], "targets": [], "gaps": []}, "capability": {"state": "complete", "requirements": [{"capability_id": "capability:computational_analysis", "label": "Computational analysis platform", "assay_families": ["meta_analysis", "machine_learning", "survival_analysis", "statistical_regression", "pca", "molecular_docking", "network_analysis", "differential_expression", "gwas"], "availability_state": "owned", "tier_unlocked": "R1", "candidate": "Automated Assays Laravel application and simulated adapters"}], "gaps": []}, "readiness": {"state": "blocked", "tier": "R4", "blocking_axis": "data", "blocked_on": "data:accession_absent", "axes": {"method": {"tier": "R1", "expressible": true, "required_operations": ["cox_ph"], "missing_operations": [], "basis": "The paper names the method it used and the corpus's method extractor maps it onto the DSL catalogue: cox_proportional_hazards."}, "capability": {"tier": "R1", "capability_id": "capability:computational_analysis", "availability_state": "owned", "basis": "The computational analysis is owned. The physical bench the paper used is not, so a physical validation cannot be run here."}, "data": {"tier": "R4", "reachable": false, "accessions": [], "resolved_accessions": [], "statements": ["Dryad. doi:10.5061/dryad.qjq2bvqf6"], "basis": "The paper names no accession to its source data, so the data has to come from the authors."}}, "can_run": {"dsl_operations": ["cox_ph"], "assets": ["source:pmid:33983065", "asset:table:pmid:33983065:1", "asset:table:pmid:33983065:2"], "steps": ["run_analysis"]}, "must_build": {"dsl_operations": [], "converters": [], "readers": [], "capabilities": [], "data_gaps": ["data:geo:None"]}, "gaps": ["data:accession_absent"]}, "review": {"state": "partial", "machine_critique": {"kind": "extraction_review", "reader": {"model": "MiniMax-M3.1-Flash", "provider": "minimax", "provider_family": "minimax", "read_at": "2026-10-31T18:29:58Z", "independence": "single_reader"}, "evidence_check": {"method": "verbatim", "availability": null}, "calls": 3, "usage": {"prompt_tokens": 19354, "completion_tokens": 1610, "cached_tokens": 6664}}, "human_critique": null, "stages": [{"id": "extraction", "state": "complete", "reader": "MiniMax-M3.1-Flash", "provider": "minimax"}], "gaps": ["review.independent_reader", "review.machine_critique", "review.human_critique"]}, "execution": {"state": "absent", "status": "not_run", "mode": null, "runs": [], "gaps": ["execution.not_run"]}, "provenance": {"entities": [{"id": "pmid:33983065", "type": "paper", "label": "pmid:33983065"}, {"id": "source:pmid:33983065", "type": "manuscript", "label": "PMID 33983065 full text"}, {"id": "data:geo:None", "type": "dataset", "label": "GEO None"}], "activities": [{"id": "activity-reading-sci-2026-11-01", "type": "classification", "used": [{"id": "pmid:33983065", "type": "paper", "label": "pmid:33983065"}, {"id": "source:pmid:33983065", "type": "manuscript", "label": "PMID 33983065 full text"}, {"id": "data:geo:None", "type": "dataset", "label": "GEO None"}], "agent": "agent:corpus-assay-engine"}, {"id": "activity-read-33983065", "type": "extraction", "used": ["source:pmid:33983065"], "agent": "agent:minimax-reader"}, {"id": "activity-resolve-None", "type": "accession_resolution", "used": ["data:geo:None"], "agent": "agent:corpus-assay-engine"}], "agents": [{"id": "agent:corpus-assay-engine", "type": "software", "label": "Corpus assay engine"}, {"id": "agent:minimax-reader", "type": "software", "label": "MiniMax literature reader"}], "source_run_id": "reading-sci-2026-11-01", "dsl_catalogue_fingerprint": "343fb30756ba6ec3", "capability_table_fingerprint": "2cb3e42f047d2ecf", "snapshot_id": "ba34b49490d9bfaf"}, "lineage": {"parent_id": "pmid:33983065", "parent_hash": "sha256:067fec14e303e5854ea3e758d33ba6cb6e557230caf24cde37b0da1c749937b1", "fork_of": null, "generation": 6}, "gaps": ["execution.not_run", "review.human_critique", "review.independent_reader", "review.machine_critique", "step:obtain_source_data blocked on data:accession_absent"], "assays": [{"role": "data_generation", "definition_id": "clinical_trial", "definition_version": "99e1195c7d6f", "definition_digest": null, "required_operations": [], "support_state": "partial", "source_hashes": {"assay_lexicon": "99e1195c7d6f"}, "confidence": 0.99, "evidence": ["oxycycline for treating COVID-19 symptoms: a randomized trial.", "with COVID-19 infection. METHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVID-19 s", "on. METHODS: This was a randomized, blinded, placebo-controlled trial in patients with mild-to-moderate COVI", "ted with at least one comorbidity (Table 2). Patients were randomly assigned to the trial within a median (IQR) of 4 (3–5"], "order_basis": "paper_text_order:32", "id": "assay:1"}, {"role": "analysis", "definition_id": "survival_analysis", "definition_version": "f2132e96ae6c7a4e", "definition_digest": null, "required_operations": ["cox_ph"], "support_state": "supported", "source_hashes": {"dsl_catalogue": "f2132e96ae6c7a4e"}, "confidence": 1.0, "evidence": ["The difference in median recovery time was determined using Kaplan–Meier analysis and a log-rank test. Details of patients who were lost to follow-up, had died, or had withdrawn from the trial owing to adverse effects were censored on the final study day. Differences in the clinical improvement in the three disease categories were analyzed using logistic regression. Hazard ratios (HRs) were calculated using Cox regression analysis."], "order_basis": "consumes_earlier_output", "id": "assay:2"}]}